Thrombotic microangiopathies: From animal models to human disease and cure

Contributions to Nephrology

Volumn 169, Issue , 2011, Pages 337-350

  Caprioli, Jessica ^a   Remuzzi, Giuseppe ^a,b   Noris, Marina ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; COMPLEMENT; SHIGA TOXIN;

ANIMAL; ARTICLE; DISEASE MODEL; DOG; GENETICS; HEMOLYTIC UREMIC SYNDROME; HUMAN; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; PLASMA; RABBIT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSGENIC MOUSE;

ADAM PROTEINS; ANIMALS; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; DOGS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PLASMA; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RABBITS; SHIGA TOXINS; THROMBOTIC MICROANGIOPATHIES;

EID: 84925933660     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000314579     Document Type: Article

References (116)

1. Copelovitch L, Kaplan BS: The thrombotic microangiopathies. Pediatr Nephrol 2008;23:1761-1767.
2. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-846. (Pubitemid 34205784)
3. Kaplan BS, Meyers KE, Schulman SL: The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 1998;9:1126-1133.
4. Besbas N, et al: A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006;70:423-431.
5. Tsai HM, Lian EC: Antibodies to von Willebrand factor- cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
6. Galbusera M, Noris M, Remuzzi G: Inherited thrombotic thrombocytopenic purpura. Haematologica 2009;94:166-170.
7. Thorpe CM: Shiga toxin- producing Escherichia coli infection. Clin Infect Dis 2004;38:1298-1303.
8. Karmali MA, et al: Sporadic cases of haemolytic- uraemic syndrome associated with faecal cytotoxin and cytotoxin- producing Escherichia coli in stools. Lancet 1983;1:619-20.
9. Riley LW, et al: Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983;308:681-685.
10. Noris M, Remuzzi G: Hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:1035-1050.
11. Constantinescu AR, et al: Nonenteropathic hemolytic uremic syndrome: causes and short- term course. Am J Kidney Dis 2004;43:976-982.
12. Noris M, Remuzzi G: Atypical hemolytic uremic syndrome. New Engl J Med 2009;361:1676-1687.
13. Jokiranta TS, et al: Where next with atypical hemolytic uremic syndrome? Mol Immunol 2007;44:3889-3900.
14. Bresin E, et al: Outcome of renal transplantation in patients with non- Shiga toxin- associated haemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88-99.
15. Loirat C, Noris M, Fremeaux- Bacchi V: Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-1972.
16. Ariceta B, et al: Guideline for the investigation and initial therapy of diarrhea- negative hemolytic uremic syndrome. Pediatr Nephrol 2009;24:687-696.
17. Vesely SK, et al: ADAMTS13 activity in thrombotic thrombocytopenic purpura- hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68.
18. Zheng XL, et al: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4043-4049.
19. Scheiring J, Andreoli SP, Zimmerhackl LB: Treatment and outcome of Shiga- toxin- associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008;23:1749-1760.
20. Wong CS, et al: The risk of the hemolytic- uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-1936.
21. Tarr PI, Gordon CA, Chandler WL: Shiga- toxin- producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073-1086.
22. Caprioli J, et al: Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108:1267-1279.
23. Furlan M, et al: von Willebrand factor- cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic- uremic syndrome. N Engl J Med 1998;339:1578-1584. (Pubitemid 28536132)
24. Soejima K, Nakagaki T: Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol 2005;42:56-62.
25. Upshaw JD Jr: Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978;298:1350-1352.
26. Moake JL: Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
27. Kokame K, et al: Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor- cleaving protease activity. Proc Natl Acad Sci USA 2002;99:11902-11907.
28. Matsumoto M, et al: Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw- Schulman syndrome. Blood 2004;103:1305-1310.
29. Uchida T, et al: Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004;104:2081-2083.
30. Donadelli R, et al: In- vitro and invivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006;96:454-464.
31. Lotta LA GI, Cairo A, Klaassen R, Metin A, Gurgey A, et al: Genotypephenotype correlation in congenital ADAMTS13 deficient patients. Blood 2008; ASH Annual Meeting Abstracts (112):273.
32. Schneppenheim R, et al: A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost 2006;96:3-6.
33. Garagiola I, et al: Nonsense- mediated mRNA decay in the ADAMTS13 gene caused by a 29- nucleotide deletion. Haematologica 2008;93:1678-1685.
34. Dong JF, et al: ADAMTS- 13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033-4039.
35. Motto DG, et al: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13- deficient mice. J Clin Invest 2005;115:2752-2761.
36. Banno F, et al: Identification of strainspecific variants of mouse Adamts13 gene encoding von Willebrand factor- cleaving protease. J Biol Chem 2004;279:30896-30903.
37. Banno F, et al: Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006;107:3161-3166.
38. Trionfini P, Tomasoni S, Galbusera M, et al: Adenoviral- mediated gene transfer restores plasma ADAMTS13 antigen activity in ADAMTS13 knockout mice. Gene Ther 2009;16:1373-1379.
39. Niiya M, et al: Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther 2009;17:34-41.
40. Laje P, et al: Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell- mediated gene therapy. Blood 2009;113:2172-2180.
41. Mohlke KL, et al: Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineagespecific expression of a glycosyltransferase. Cell 1999;96:111-120.
42. Chauhan AK, et al: The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008;111:3452-3457.
43. Burns ER, Zucker- Franklin D: Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 1982;60:1030-1037.
44. Chauhan AK, et al: Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006;203:767-776.
45. Banatvala N, et al: The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical and epidemiologic findings. J Infect Dis 2001;183:1063-1070.
46. Mead PS, Griffin PM: Escherichia coli O157:H7. Lancet 1998;352:1207-1212.
47. Milford D: The hemolytic uremic syndromes in the United Kingdom; in Kaplan BS, Trompeter RS, Moake JL (eds): Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York, Marcel Dekker Inc., 1992, pp 39- 59.
48. Garg AX, et al: Long- term renal prognosis of diarrhea- associated hemolytic uremic syndrome: a systematic review, meta- analysis, and metaregression. JAMA 2003;290:1360-1370.
49. Donnenberg MS, et al: Role of the eaeA gene in experimental enteropathogenicEscherichia coli infection. J Clin Invest 1993;92: 1412-1417.
50. Hurley BP, Thorpe CM, Acheson DW: Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001;69:6148-6155.
51. Nakajima H, et al: Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem 2001;276:42915-42922.
52. Obrig TG, Moran TP, Brown JE: The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 1987;244:287-294.
53. Morigi M, et al: Verotoxin- 1- induced up- regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001;98:1828-1835.
54. Ruggeri Z: Endothelial cells: they only look all alike. Blood 2001;98:1644.
55. Richardson SE, et al: Experimental verocytotoxemia in rabbits. Infect Immun 1992;60:4154-4167.
56. Tesh VL, Samuel JE, Burris JA, Owens JW, Taylor FBJ, Siegler RL: Quantitation and localization of shiga toxin/shiga-like toxin-binding glycolipid receptors in human and babbon tissues. in: Recent Advances in Verocytotoxin-Producing Escherichia Coli Infections, edited by Karmali MA, Goglio AG, Bergamo, Italy, Elsevier Science BV, 1994, pp 189-192.
57. Taylor CM, et al: A laboratory model of toxin- induced hemolytic uremic syndrome. Kidney Int 1999;55:1367-1374.
58. Siegler RL, et al: Response to single and divided doses of Shiga toxin- 1 in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol 2001;12:1458-1467.
59. Siegler RL, et al: Response to Shiga toxin- 1, with and without lipopolysaccharide, in a primate model ofhemolytic uremic syndrome. Am J Nephrol 2001;21:420-425.
60. Siegler RL, et al: Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 2003;18:92-96.
61. Tesh VL, et al: Comparison of the relative toxicities of Shiga- like toxins type I and type II for mice. Infect Immun 1993;61:3392-3402.
62. OBrien AD, et al: Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 1992;180:65-94.
63. Carpenter JL, et al: Idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet Pathol 1988;25:401-407.
64. Hertzke DM, et al: Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet Pathol 1995;32:451-459.
65. Wadolkowski EA, et al: Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga- like toxin type II. Infect Immun 1990;58:3959-3965.
66. Karpman D, et al: The role of lipopolysaccharide and Shigalike toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997;175:611-620.
67. Wadolkowski EA, Burris JA, and OBrien AD, Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun 1990;58:2438-2445.
68. Rutjes NW, et al: Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int 2002;62:832-845.
69. Wolski VM, Soltyk AM, Brunton JL: Tumour necrosis factor alpha is not an essential component of verotoxin 1- induced toxicity in mice. Microb Pathog 2002;32:263-271.
70. Dran GI, et al: Protective role of nitric oxide in mice with Shiga toxininduced hemolytic uremic syndrome. Kidney Int 2002;62:1338-1348.
71. Keepers TR, et al: A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 2006;17: 3404-3414.
72. Zanchi C, et al: Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol 2008;181:1460-1469.
73. Pavia AT, et al: Hemolytic- uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990;116: 544-551.
74. Chaisri U, et al: Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome. Microb Pathog 2001;31:59-67.
75. Psotka MA, et al: Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun 2009;77:959-969.
76. Paixao- Cavalcante D, et al: Shiga toxin- 2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H- deficient mice. Clin Exp Immunol 2009;155:339-347.
77. Palermo MS, et al: Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin- 2 in a mouse model. Clin Exp Immunol 1999;116:462-467.
78. Palermo M, et al: Pretreatment of mice with lipopolysaccharide (LPS) or IL- 1beta exerts dose- dependent opposite effects on Shiga toxin- 2 lethality. Clin Exp Immunol 2000; 119:77-83.
79. Ikeda M, Ito S, Honda M: Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga- like toxin. Pediatr Nephrol 2004;19:485-489.
80. Roche JK, et al: CXCL1/KC and CXCL2/MIP- 2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7- associated renal inflammation. Am J Pathol 2007;170:526-537.
81. Harel Y, et al: A reporter transgene indicates renal- specific induction of tumor necrosis factor (TNF) by Shiga- like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 1993;92:2110-2116.
82. Liu XH, Lingwood CA, Ray PE: Recruitment of renal tubular epithelial cells expressing verotoxin- 1 (Stx1) receptors in HIV- 1 transgenic mice with renal disease. Kidney Int 1999;55:554-561.
83. Clayton F, et al: Lipopolysaccharide upregulates renal Shiga toxin receptors in a primate model of hemolytic uremic syndrome. Am J Nephrol 2005;25:536-540.
84. van Setten PA, et al: Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997;51:1245-1256.
85. Isogai E, et al: Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection. Microbiol Immunol 2000;44:89-95.
86. Zhang Q, et al: Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis 2009;199:486-493.
87. Gao X, et al: Immunogenicity of a novel Stx2B- Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2009;27:2070-2076.
88. Gu J, et al: Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes Infect 2009;11:835-841.
89. Noris M, et al: Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999;10:281-293.
90. Warwicker P, et al: Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836-844.
91. Thompson RA, Winterborn MH: Hypo complementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981;46:110-119.
92. Pichette V, et al: Familial hemolyticuremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994;24:936-941.
93. Rougier N, et al: Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998;9:2318-2326.
94. Delvaeye M, et al: Thrombomodulin mutations in atypical hemolytic uremic syndrome. New Engl J Med 2009;361:345-357.
95. Fremeaux- Bacchi V, et al: Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008;112:4948-4952.
96. Dragon- Durey MA, et al: Anti- Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-563.
97. Zipfel PF, Skerka C: Complement factor H and related proteins: an expanding family of complementregulatory proteins? Immunol Today 1994;15:121-126.
98. Rodriguez de Cordoba S, et al: The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004;41:355-367.
99. Manuelian T, et al: Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003;111:1181-1190.
100. Sanchez- Corral P, et al: Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004;41:81-84.
101. Jozsi M, et al: Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. Histol Histopathol 2004;19:251-258.
102. Appel GB, et al: Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16:1392-1403.
103. Mullins RF, Aptsiauri N, Hageman GS: Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye (Lond) 2001;15:390-395.
104. Zipfel PF, et al: Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006;43:97-106.
105. Montes T, et al: Genetic deficiency of complement factor H in a patient with age- related macular degeneration and membranoproliferative glomerulonephritis. Mol Immunol 2008;45:2897-2904.
106. Ault BH, et al: Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997;272: 25168-25175.
107. Dragon- Durey MA, et al: Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol, 2004;15:787-795.
108. Jansen JH, Hogasen K, Mollnes TE: Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol 1993;143:1356-1365.
109. Jansen JH, et al: In situ complement activation in porcine membranoproliferative glomerulonephritis type II. Kidney Int 1998;53:331-349.
110. Hogasen K, et al: Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995;95:1054-1061.
111. Jansen JH, Hogasen K, Grondahl AM: Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H. Vet Rec 1995;137:240-244.
112. Hegasy GA, et al: The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002;161:2027-2034.
113. Hogasen K, Jansen JH, Harboe M: Eradication of porcine factor H deficiency in Norway. Vet Rec 1997;140:392-395.
114. Pickering MC, et al: Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002;31:424-428.
115. Pickering MC, et al: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007;204:1249-1256.
116. Jorge E, Cook HT, Botto M, Pickering MC: Insights into the role of complement dysregulation in atypical haemolytic uremic syndrome. Mol Immunol 2009;46:2851.